Human B7-2 / CD86 Protein, His Tag, low endotoxin (MALS verified)

ユーザーレビュー
製品番号/仕様
価格
数量
CD6-H5223-100ug
$305.00
CD6-H5223-1mg (250ug X 4)
$1980.00
ETA of in-stock products:2 business days
総アイテム数 製品金額$ 0

製品詳細

  • Synonyms

    CD86, B7-2, B70, CD28LG2, LAB72, MGC34413

  • Source

    Human B7-2, His Tag (CD6-H5223) is expressed from human 293 cells (HEK293). It contains AA Leu 26 - Pro 247 (Accession # AAH40261).

    Predicted N-terminus: Leu 26

    Request for sequence
  • Molecular Characterization

    B7-2 Structure

    Other Tags and Version Biotin & Other Labeled Version

    This protein carries a polyhistidine tag at the C-terminus.

    The protein has a calculated MW of 26.2 kDa. The protein migrates as 40-63 kDa when calibrated against Star Ribbon Pre-stained Protein Marker under reducing (R) condition (SDS-PAGE) due to glycosylation.

  • Endotoxin

    Less than 0.01 EU per μg by the LAL method / rFC method.

  • Purity

    >90% as determined by SDS-PAGE.

    >95% as determined by SEC-MALS.

  • Formulation

    Lyophilized from 0.22 μm filtered solution in PBS, pH7.4 with trehalose as protectant.

    Contact us for customized product form or formulation.

  • Reconstitution

    Please see Certificate of Analysis for specific instructions.

    For best performance, we strongly recommend you to follow the reconstitution protocol provided in the CoA.

  • Shipping and Storage

    This product is shipped at ambient temperature.

    For long term storage, the product should be stored at lyophilized state at -20°C or lower.

    Please avoid repeated freeze-thaw cycles.

    This product is stable after storage at:

    1. -20°C to -70°C for 12 months in lyophilized state;
    2. -70°C for 3 months under sterile conditions after reconstitution.
  • ACRO Quality Management System

    1. QMS(ISO, GMP)
    2. Quality Advantages
    3. Quality Control Process

お客様はこちらも閲覧

データ表示

  • SDS-PAGE

    B7-2 SDS-PAGE

    Human B7-2, His Tag on SDS-PAGE under reducing (R) condition. The gel was stained with Coomassie Blue. The purity of the protein is greater than 90% (With Star Ribbon Pre-stained Protein Marker).

  • SEC-MALS

    B7-2 SEC-MALS

    The purity of Human B7-2, His Tag (Cat. No. CD6-H5223) is more than 95% and the molecular weight of this protein is around 40-50 kDa verified by SEC-MALS.

    Report
  • Bioactivity-ELISA

     B7-2 ELISA

    Immobilized Biotinylated Human CTLA-4, Fc,Avitag (Cat. No. CT4-H82F3) at 5 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with a linear range of 0.01-2.5 μg/mL (QC tested).

    Protocol
  • Bioactivity-BLI

     B7-2 BLI

    Loaded Human / Cynomolgus / Rhesus macaque CD28, Fc Tag (Cat. No. CD8-H525a) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 6.8 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol
  •  B7-2 BLI

    Loaded Human CTLA-4, Fc Tag (Cat. No. CT4-H5255) on Protein A Biosensor, can bind Human B7-2, His Tag (Cat. No. CD6-H5223) with an affinity constant of 1.9 μM as determined in BLI assay (ForteBio Octet Red96e) (Routinely tested).

    Protocol

ユーザーレビュー
コメントを投稿

バックグランド

Cluster of Differentiation 86 (CD86) is also known as B-lymphocyte activation antigen B7-2, is a type I membrane protein that is a member of the immunoglobulin superfamily, and is constitutively expressed on interdigitating dendritic cells, Langerhans cells, peripheral blood dendritic cells, memory B cells, and germinal center B cells. Additionally, B72 is expressed at low levels on monocytes and can be upregulated through interferon γ. CD86 is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD86 works in tandem with CD80 to prime T cells. Recent study has revealed that B7-2 promotes the generation of a mature APC repertoire and promotes APC function and survival. Furthermore, the B7 proteins are also involved in innate immune responses by activating NF-κB-signaling pathway in macrophages. CD86 thus is regarded as a promising candidate for immune therapy. CD86+ macrophages in Hodgkin lymphoma patients are an independent marker for potential nonresponse to firstline-therapy.

最新の進展

 
医薬品開発の進捗
  • 英語名:

    Cluster of differentiation 86

  • カテゴリ:

  • 市販の医薬品数:

    2 詳細

  • 治験医薬品数:

    7 詳細

  • 最新の開発ステージ:

    Approved

お問い合わせ
医薬品候補ライセンス
他の関連情報
  • 製品情報
  • 製品詳細
  • お客様はこちらも閲覧
  • データ表示
  • ユーザーレビュー
  • 背景
お問い合わせ

お問い合わせ
グローバル:+1 800-810-0816(Toll Free)

メールアドレス
order.jp@acrobiosystems.com

アクロバイオシステムズ株式会社
〒101-0051
東京都千代田区神田神保町1-32-8